Information Provided By: 
Fly News Breaks for August 8, 2019
CPRX
Aug 8, 2019 | 11:02 EDT
Catalyst Pharmaceuticals' better than expected Firdapse sales in the second quarter of launch indicates continued strong execution and success in both transitioning historical patients to commercial product as well as reaching new naive patients, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. He took up his near-term estimates and boosted his price target for Catalyst shares to $8 from $7.50 while maintaining an Overweight rating on the name.
News For CPRX From the Last 2 Days
There are no results for your query CPRX
